Regeneron Pharmaceuticals (Nasdaq: REGN) and Sanofi (Euronext Paris: SAN; Nasdaq: SNY) have expanded their global antibody alliance to co-develop and co-commercialize four Regeneron-invented, long-acting antibodies targeting the IL-13, IL-4×IL-13, IL-4, and IL-4Rα pathways. Sanofi will pay Regeneron USD 1 billion upfront and up to an additional USD 7 billion in development, regulatory, and commercial milestones.
The lead asset, REGN20423, is a long-acting IL-13 monoclonal antibody currently in a Phase I trial for atopic dermatitis. The other three programs — a long-acting IL-4×IL-13 bispecific antibody and monoclonal antibodies targeting IL-4 and IL-4Rα — are preclinical and expected to enter clinical studies in 2027.
Under the agreement, the companies will share development and commercialization costs equally and split future profits 50:50 globally. Regeneron will lead research and development, while Sanofi will lead global commercialization.
Regeneron also gains an option to include Sanofi's lunsekimig, an investigational TSLP×IL-13 bispecific Nanobody VHH therapy, in the collaboration following completion of its Phase III COPD trials.